Sanofi to invest $638m in new Singapore vaccine production site

Construction is expected to begin in Q3 of 2021.

Biopharmaceutical company Sanofi is going to invest $638m (€400m) over five years to create a vaccine production centre in Singapore, in partnership with the Singapore Economic Development Board (EDB). The facility will supply vaccines to Asia and complement existing manufacturing capacities in Europe and North America.

The new site will provide Sanofi with the ability to produce vaccines on a massive scale for Asia, and quickly respond to future pandemic risks.

“As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.

The construction is expected to begin in Q3 2021, and is expected to be fully operational in Q1 2026, once all qualifications and validations have been completed.

Also Read

SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement

Cordlife Group aims to raise $8.04m in private placement

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit